Drug profile · INN
afamelanotide
SCENESSE
afamelanotide (SCENESSE) is a melanocortin receptor 1 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — afamelanotide
- US status
- approved
- Class
- Dermatologicals (D02)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
afamelanotide (SCENESSE) is a melanocortin receptor 1 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Melanocortin receptor 1 agonist
Primary target: Melanocyte-stimulating hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is afamelanotide?
afamelanotide (SCENESSE) is a melanocortin receptor 1 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for afamelanotide?
SCENESSE is a marketed brand name for afamelanotide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of afamelanotide?
afamelanotide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.